Detection of EBV DNA in clinically ill patients from 2013 to 2023 in Beijing, China

2013年至2023年中国北京临床患病患者EBV DNA检测情况

阅读:1

Abstract

OBJECTIVE: To investigate the epidemiological characteristics and infection patterns of Epstein-Barr virus (EBV) among patients at Peking Union Medical College Hospital (PUMCH) between 2013 and 2023, with a concurrent analysis of the clinical manifestations and laboratory parameters observed in patients diagnosed with EBV-associated infectious mononucleosis (IM). METHODS: A retrospective analysis was conducted on data from 76,135 patients who underwent EBV DNA testing at Peking Union Medical College Hospital between 2013 and 2023. Additionally, clinical data from 152 patients diagnosed with IM from 2013 to 2024 were collected, with their clinical manifestations and laboratory parameters thoroughly evaluated. RESULTS: The overall EBV DNA positivity rate was 6.77%, with significant variations observed across different years and age groups. The detection rate of EBV DNA in males was significantly higher than in females, with the highest detection rate observed in individuals aged over 71 years. A decline in EBV DNA detection frequency was noted during the post-COVID-19 pandemic period (2020-2023). Among EBV-related clinical entities, the highest EBV DNA positive rate (37.4%) was observed in patients with IM. In this cohort, liver function abnormalities were common: elevations of alanine aminotransferase (ALT) and aspartate aminotransferase (AST) by 1- to 5-fold above the upper limit of normal were present in 61 (57%) and 41 (59%) cases, respectively. Immunophenotypic analysis revealed a marked increase in the CD8 + DR+/CD8 + ratio in 67 patients (99%), accompanied by a reduction in CD19 + B-lymphocyte percentage in 62 cases (90%), indicating pronounced immune activation and B-cell suppression characteristic of acute EBV infection. CONCLUSION: The positive rates of EBV DNA showed sex differences and significant fluctuations between 2013 and 2023, without displaying a consistent upward trend. Persistent surveillance and heightened clinical awareness (laboratory parameters, such as ALT, AST and CD8 + DR+/CD8+) are warranted, particularly regarding IM attributable to EBV.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。